October 10, 2016
RetinoStat Phase I study results confirm utility of Oxford BioMedica’s LentiVector delivery platform for the treatment of chronic disease
Oxford BioMedica, a UK-based gene and cell therapy group, has published results from the RetinoStat (OXB-201) Phase I study in patients with advanced wet age-related macular degeneration (AMD) in the journal Human Gene Therapy.